Client News
Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action
5th January 2023
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
3rd January 2023
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
3rd January 2023
Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022
22nd December 2022
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
21st December 2022
Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD
20th December 2022
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
20th December 2022
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
16th December 2022
There is no more content to load